This definition appears very rarely
and is found in the following Acronym Finder categories:
See other meanings of MSP
We have 630 other definitions for MSP
in our Acronym Attic
Samples in periodicals archive:
Graham also served as Chair of the Board of Directors of Rx&D, the national association representing research-based pharmaceutical companies in Canada, as well as Chair of the Board of the Merck/Schering-Plough joint venture.
The defendants include Schering, certain of Schering's former directors and officers, the underwriters that participated in public offerings of Schering stock in August 2007, and Merck/Schering-Plough Pharmaceuticals, the joint venture formed by Schering and Merck to market VYTORIN and another anti-cholesterol drug product, ZETIA.
Time to Talk CARDIO is supported in part by Merck/Schering-Plough Pharmaceuticals, and it was developed in partnership with the American Academy of Family Physicians, Canyon Ranch Institute, and RIASWorks, a company that supports the development of medical communication tools.
Companies Mentioned: * Abbott Labs * Amgen * AstraZeneca * Bayer/Schering AG * Boehringer Ingelheim * Bristol-Myers Squibb * Daiichi-Sankyo/Ranbaxy * Eisai/MGI Pharma * Eli Lilly * GlaxoSmithKline * Johnson & Johnson * Merck * Merck KGaA/Serono * Merck/Schering-Plough * Novartis * Novo Nordisk * Nycomed/Altana Pharma * Pfizer * Pfizer/Wyeth * Roche * Roche/Genentech * Sanofi-Aventis * Schering-Plough * Schering-Plough/Organon * Takeda * Takeda/Millennium * Teva * Teva/Barr Labs * UCB/Schwarz Pharma * Wyeth For more information visit http://www.
Under the terms of the agreement, following the closing of the Merck/Schering-Plough merger, Sanofi-aventis would have an option to combine the Intervet/Schering-Plough Animal Health business with Merial to form an animal health joint venture that would be owned equally by the new Merck and Sanofi-aventis.
According to the new report entitled Brands & Strategies: Lipid-Modifying Agents, although Merck/Schering-Plough revenue will decline because of the negative perception, the reduction in sales will be predominately US-based, and in part, will be offset by modest growth in Europe.
Schechter has held a number of senior leadership positions including responsibility for Merck's global pharmaceutical franchises and general manager of the Merck/Schering-Plough cholesterol joint venture.
This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture.